Repeat exposure to active tuberculosis and risk of re-infection

• 1 Liverpool Hospital, Sydney, NSW
• 2 UNSW Australia, Sydney, NSW
• 3 Westmead Hospital, Sydney, NSW

---

• 1. Saukkonen JJ, Cohn DL, Jasmer RM, et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med 2006; 174: 935-952.
• 2. Supply P, Allix C, Lesjean S, et al. Proposal for standardization of optimized mycobacterial interspersed repetitive unit-variable-number tandem repeat typing of Mycobacterium tuberculosis. J Clin Microbiol 2006; 44: 4498-4510.
• 3. Comstock GW. How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults? Int J Tuberc Lung Dis 1999; 3: 847-850.
• 4. Dobler CC, Crawford AB, Jelfs PJ, et al. Recurrence of tuberculosis in a low-incidence setting. Eur Respir J 2009; 33: 160-167.
• 5. World Health Organization. Guidelines on the management of latent tuberculosis infection. Geneva: WHO, 2015.
• 6. O’Shea MK, Fletcher TE, Beeching NJ, et al. Tuberculin skin testing and treatment modulates interferon-gamma release assay results for latent tuberculosis in migrants. PLoS One 2014; 9: e97366.
• 7. Pollock NR, Kashino SS, Napolitano DR, et al. Evaluation of the effect of treatment of latent tuberculosis infection on QuantiFERON-TB gold assay results. Infection Control 2009; 30: 392-395.
• 8. Huang YS, Chern HD, Su WJ, et al. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis. Hepatology 2002; 35: 883-889.
• 9. Ohno M, Yamaguchi I, Yamamoto I, et al. Slow N-acetyltransferase 2 genotype affects the incidence of isoniazid and rifampicin-induced hepatotoxicity. Int J Tuberc Lung Dis 2000; 4: 256-261.